RxDoctor Payments Data

Jad Omran, MD

Interventional Cardiology · la Jolla, CANPI 1366720211

Payments from drug & device makers

$99,290in general payments, 2019–2025

Across 636 payments — averaging $156.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Philips North America LLC$25K
  • Shockwave Medical, Inc$17K
  • Medtronic$13K
  • Abbott$13K
  • Abiomed$8K
  • Stryker$5K
  • plus $18K from 38 others

What the payments were for

  • Consulting fees$22,41523%
  • Speaking & faculty fees$47,87948%
  • Travel & lodging$6,9477%
  • Food & beverage$21,86022%
  • Education$1890%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$99,290 in reported general payments places this provider in the 80th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$411,831
Medicare patients
678
Services billed
2,713

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban314$311,532
EntrestoSacubitril/Valsartan190$173,962
XareltoRivaroxaban175$163,240
JardianceEmpagliflozin94$87,797
BrilintaTicagrelor42$32,521
MultaqDronedarone Hcl12$9,633
Ranolazine ErRanolazine107$4,864
ClopidogrelClopidogrel Bisulfate386$3,145
Atorvastatin Calcium337$2,428
Prasugrel Hcl17$2,265
Metoprolol Succinate206$2,243
Rosuvastatin Calcium80$1,581
Bumetanide61$1,580
Nitroglycerin109$1,473
Losartan Potassium181$1,344

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$306$311,532314 claims
NovartisEntresto$494$173,962190 claims
Johnson & JohnsonXarelto$488$163,240175 claims
Boehringer IngelheimJardiance$79$87,79794 claims
AstraZenecaBrilinta$244$32,52142 claims
Sanofi-aventis U.S. LLCMultaq$58$9,63312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in la Jolla

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →